Objective: To evaluate the efficacy and toxic reactions of Endostar combined with TP chemo-therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Methods: A total of 68 cases of advanced stage NSCLC confirmed by pathohistology or cytology were randomly divided into two treate-ment groups: the Endostar combined with TP chemotherapy group (37 cases) and the simple TP chemothera-py group (31 cases). Patients in the Endostar combined with TP chemotherapy group were treated with TXT 65mg/m~2 on d2 and d9, DDP 75 mg/m~2, d1-4; and endostar 15g, d1-14. Patients in the simple chemotherapy group were treated with TXT and DDP. After 2 weeks, we estimated the recent curative effect and toxic reac-tions according to WHO standard. Results: The total response rates in the two groups were 56.8% and 29.7%, respectively, with a significant difference (X~2=4.08, P<0.05). The main toxic reactions were bone marrow sup-pression, gastrointestinal reactions and hair loss. And the incidences of the above three toxic reactions were 59.4%, 39.1%, and 81.1% in the endostar combined with chemotherapy group and 64.5%, 38.7%, and 83.9% in the simple chemothotherapy group. The toxic reactions were mainly related to chemotherapeutics and were not significantly different between the two groups (P>0.05). Conclusion: Endostar combined with chemothera-py is a safe method to treat advanced stage NSCLC. Endostar can improve the curative effect of chemothera-py. This method deserves to be clinically practiced and observed further.